Home » Newsletters » BioWorld

BioWorld

March 4, 1994

View Archived Issues

SEQUANA AND KAISER SEEK GENETIC CAUSE OF DIABETES

THIRD PHASE I ON ARTHRITIS VACCINE

ORACLE TO INTRODUCE SALIVA-BASED HIV TEST

CENTOCOR EXTENDS ACQUISITION DATE

BLECH AND CO. EXERCISES RIBI WARRANTS

PROTEIN DESIGN LABS ANNOUNCES TRIAL RESULTS

VIRAGEN TO SEEK PRIVATE PLACEMENT

THYMOSIN ALPHA 1 IN PHASE III TRIALS

INHALE FILES FOR IPO

THYMOSIN BOOSTS IMMUNE RESPONSE

AMI, ASTRA/MERCK TEAM FOR ULCER DRUG

RAC APPROVES TWO TRIALS

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...